---
title: "What's Going On With Shattuck Labs Stock Wednesday?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289340241.md"
description: "Shattuck Labs (STTK) shares fluctuated after pricing a $75 million public offering at $4.00 per share for approximately 10.88 million shares, plus pre-funded warrants. The company, a clinical-stage biotech focused on DR3-blocking antibodies, anticipates closing the deal on June 11, 2026. Technically, STTK trades below its 20-day and 50-day SMAs with an RSI indicating oversold conditions, though it remains up significantly over the past year."
datetime: "2026-06-10T13:40:40.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289340241.md)
  - [en](https://longbridge.com/en/news/289340241.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289340241.md)
generator: "portal-rs"
---

# What's Going On With Shattuck Labs Stock Wednesday?

**Shattuck Labs, Inc.** (NASDAQ:STTK) shares are volatile in Wednesday’s session after the company announced the pricing of a public offering of its common stock.

The offering is expected to generate approximately $75 million before deducting underwriting discounts and commissions, which may impact investor sentiment.

## Shattuck Labs Public Offering

Shattuck Labs has priced its public offering at $4.00 per share for 10,879,376 shares, along with pre-funded warrants at $3.9999 per warrant.

The offering is anticipated to close on June 11, 2026, subject to customary closing conditions.

Shattuck Labs is a clinical-stage biotechnology company focused on developing monoclonal and bispecific DR3-blocking antibodies, including potential first-in-class therapies, for inflammatory and immune-mediated diseases.

## STTK Technical Analysis

From a longer-term trend lens, STTK is still holding just above its 200-day SMA at $4.01, but it’s trading 22.2% below its 20-day SMA ($5.67) and 32% below its 50-day SMA ($6.49), which keeps the intermediate trend pointed down.

The 20-day SMA sitting below the 50-day SMA adds to that bearish near-term structure, even though the stock remains up 280.17% over the past 12 months.

Momentum is the bigger story right now: RSI is 28.23, which puts the stock in oversold territory and suggests selling pressure has become stretched.

RSI is a speedometer for recent price moves—readings this low often coincide with “capitulation-style” selling where bounces can start, but it doesn’t guarantee a bottom without follow-through.

-   **Key Resistance**: $5.00 — a round-number area that also sits below the cluster of short- and medium-term moving averages, where rebounds can stall

## Shattuck Labs Price Action

**STTK Stock Price Activity:** Shattuck Labs shares were trading up 6.79% at $4.560 at the time of publication on Wednesday, according to Benzinga Pro data.

*Phot via Shutterstock*

### Related Stocks

- [STTK.US](https://longbridge.com/en/quote/STTK.US.md)

## Related News & Research

- [Connor Clark & Lunn Investment Management Ltd. Invests $1.99 Million in Shattuck Labs, Inc. $STTK](https://longbridge.com/en/news/297417449.md)
- [Shattuck Labs posts investor deck spotlighting DR3-blocking antibody SL-325 for inflammatory diseases](https://longbridge.com/en/news/295529846.md)
- [Aptevo Reports 93% Clinical Benefit Rate with Mipletamig Triplet in Difficult-to-Treat TP53-Mutated Frontline AML | APVO Stock News](https://longbridge.com/en/news/297911849.md)
- [Coya Therapeutics posts September 2026 investor presentation on neurodegeneration pipeline](https://longbridge.com/en/news/297669200.md)
- [Xenon Pharmaceuticals (NASDAQ:XENE) Insider Sells $425,847.00 in Stock](https://longbridge.com/en/news/297641840.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**